In many cancers, anti-VEGF treatment must be given continuously, but this leads to toxicity, worsening the quality of life and/or exacerbating drug resistance mediated by treatment-induced epigenetic changes; therefore, a treatment ‘holiday’ may be required to allow reversion to a previous epigenetic profile57. This evidence concerns the gene VEGFA and cancer.